ITGAM and prostate cancer: In patients with renal cancer, polymorphonuelcar MDSC have been shown to express CD11b+ CD14negCD15+CD66b+ VEGFR1+[33] whereas in patients with melanoma, prostate cancer, hepatocellular carcinoma or head and neck cancer, immunosuppressive monocytic CD11b+ CD14+ HLA-DRlow/neg MDSC were found [21,34-36].